For the first time, there are more than 1,000 active regenerative medicine and advanced therapy
developers worldwide, and of these companies, 415 are in the clinical stage of development. As the CGT industry accelerates, so will the demand for best practices, and better tools and solutions. For advanced therapies, the product and patient journey is entirely different from traditional trials. As such, biotech and pharma companies will need to overcome challenges and complexities from regulatory pathways and patient recruitment to logistics and manufacturing. CGT therapies also require specialty testing and lab services, including molecular capabilities and immunohistochemistry testing. Adopting strategic partnerships with deep CGT expertise with a broad spectrum of solutions and services is vital to the success of a development program.